Cargando…

VEGFR Inhibitors for Uterine Metastatic Perivascular Epithelioid Tumors (PEComa) Resistant to mTOR Inhibitors. A Case Report and Review of Literature

Uterine perivascular epithelioid cell tumors (PEComas) are rare neoplasms. PI3K/AKT/mTOR pathway upregulation is critical for their pathogenesis and is often associated with TSC1/TSC2 inactivation. Although first line mTOR inhibitors are an effective treatment, metastatic PEComas eventually progress...

Descripción completa

Detalles Bibliográficos
Autores principales: Liapi, Aikaterini, Mathevet, Patrice, Herrera, Fernanda G., Hastir, Delfyne, Sarivalasis, Apostolos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8032946/
https://www.ncbi.nlm.nih.gov/pubmed/33842348
http://dx.doi.org/10.3389/fonc.2021.641376
_version_ 1783676316362473472
author Liapi, Aikaterini
Mathevet, Patrice
Herrera, Fernanda G.
Hastir, Delfyne
Sarivalasis, Apostolos
author_facet Liapi, Aikaterini
Mathevet, Patrice
Herrera, Fernanda G.
Hastir, Delfyne
Sarivalasis, Apostolos
author_sort Liapi, Aikaterini
collection PubMed
description Uterine perivascular epithelioid cell tumors (PEComas) are rare neoplasms. PI3K/AKT/mTOR pathway upregulation is critical for their pathogenesis and is often associated with TSC1/TSC2 inactivation. Although first line mTOR inhibitors are an effective treatment, metastatic PEComas eventually progress. A 53-year-old woman presented a 4-month history of post-menopausal vaginal bleeding. Clinical and radiological examination detected a uterine mass and a single S1 bone lesion. The patient underwent a radical hysterectomy and bone biopsy. The anatomopathological evaluation concluded to an oligo-metastatic uterine PEComa. The tumor harbored a heterozygous deletion of 9q34 that contains the TSC1 gene. Concerning the primary lesion, the resection was complete and the single bone metastasis was treated with radiotherapy. Three months later, the patient presented bone, lung and subcutaneous metastatic progression. An everolimus and denosumab treatment was initiated. After 2 years of treatment, a clinically significant bone, lung and subcutaneous progression was detected. Following a literature review of the possible therapeutic options, we initiated a second line treatment by pazopanib. This treatment resulted in regression of the subcutaneous lesions and stability of lung and bone metastases. In this challenging, rare setting, our report suggests single agent, anti-angiogenic, tyrosine kinase inhibitor to be effective as second line treatment of metastatic uterine PEComa progressing on mTOR inhibitors.
format Online
Article
Text
id pubmed-8032946
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-80329462021-04-10 VEGFR Inhibitors for Uterine Metastatic Perivascular Epithelioid Tumors (PEComa) Resistant to mTOR Inhibitors. A Case Report and Review of Literature Liapi, Aikaterini Mathevet, Patrice Herrera, Fernanda G. Hastir, Delfyne Sarivalasis, Apostolos Front Oncol Oncology Uterine perivascular epithelioid cell tumors (PEComas) are rare neoplasms. PI3K/AKT/mTOR pathway upregulation is critical for their pathogenesis and is often associated with TSC1/TSC2 inactivation. Although first line mTOR inhibitors are an effective treatment, metastatic PEComas eventually progress. A 53-year-old woman presented a 4-month history of post-menopausal vaginal bleeding. Clinical and radiological examination detected a uterine mass and a single S1 bone lesion. The patient underwent a radical hysterectomy and bone biopsy. The anatomopathological evaluation concluded to an oligo-metastatic uterine PEComa. The tumor harbored a heterozygous deletion of 9q34 that contains the TSC1 gene. Concerning the primary lesion, the resection was complete and the single bone metastasis was treated with radiotherapy. Three months later, the patient presented bone, lung and subcutaneous metastatic progression. An everolimus and denosumab treatment was initiated. After 2 years of treatment, a clinically significant bone, lung and subcutaneous progression was detected. Following a literature review of the possible therapeutic options, we initiated a second line treatment by pazopanib. This treatment resulted in regression of the subcutaneous lesions and stability of lung and bone metastases. In this challenging, rare setting, our report suggests single agent, anti-angiogenic, tyrosine kinase inhibitor to be effective as second line treatment of metastatic uterine PEComa progressing on mTOR inhibitors. Frontiers Media S.A. 2021-03-26 /pmc/articles/PMC8032946/ /pubmed/33842348 http://dx.doi.org/10.3389/fonc.2021.641376 Text en Copyright © 2021 Liapi, Mathevet, Herrera, Hastir and Sarivalasis. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Liapi, Aikaterini
Mathevet, Patrice
Herrera, Fernanda G.
Hastir, Delfyne
Sarivalasis, Apostolos
VEGFR Inhibitors for Uterine Metastatic Perivascular Epithelioid Tumors (PEComa) Resistant to mTOR Inhibitors. A Case Report and Review of Literature
title VEGFR Inhibitors for Uterine Metastatic Perivascular Epithelioid Tumors (PEComa) Resistant to mTOR Inhibitors. A Case Report and Review of Literature
title_full VEGFR Inhibitors for Uterine Metastatic Perivascular Epithelioid Tumors (PEComa) Resistant to mTOR Inhibitors. A Case Report and Review of Literature
title_fullStr VEGFR Inhibitors for Uterine Metastatic Perivascular Epithelioid Tumors (PEComa) Resistant to mTOR Inhibitors. A Case Report and Review of Literature
title_full_unstemmed VEGFR Inhibitors for Uterine Metastatic Perivascular Epithelioid Tumors (PEComa) Resistant to mTOR Inhibitors. A Case Report and Review of Literature
title_short VEGFR Inhibitors for Uterine Metastatic Perivascular Epithelioid Tumors (PEComa) Resistant to mTOR Inhibitors. A Case Report and Review of Literature
title_sort vegfr inhibitors for uterine metastatic perivascular epithelioid tumors (pecoma) resistant to mtor inhibitors. a case report and review of literature
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8032946/
https://www.ncbi.nlm.nih.gov/pubmed/33842348
http://dx.doi.org/10.3389/fonc.2021.641376
work_keys_str_mv AT liapiaikaterini vegfrinhibitorsforuterinemetastaticperivascularepithelioidtumorspecomaresistanttomtorinhibitorsacasereportandreviewofliterature
AT mathevetpatrice vegfrinhibitorsforuterinemetastaticperivascularepithelioidtumorspecomaresistanttomtorinhibitorsacasereportandreviewofliterature
AT herrerafernandag vegfrinhibitorsforuterinemetastaticperivascularepithelioidtumorspecomaresistanttomtorinhibitorsacasereportandreviewofliterature
AT hastirdelfyne vegfrinhibitorsforuterinemetastaticperivascularepithelioidtumorspecomaresistanttomtorinhibitorsacasereportandreviewofliterature
AT sarivalasisapostolos vegfrinhibitorsforuterinemetastaticperivascularepithelioidtumorspecomaresistanttomtorinhibitorsacasereportandreviewofliterature